Cargando…

Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer

BACKGROUND: The potential use of microRNAs (miRNAs) as ideal tumor markers has been the focus of recent research. OBJECTIVE: Our hypothesis was that circulating miRNAs are differentially expressed in pretherapeutic sera of breast cancer patients compared to controls. MATERIALS AND METHODS: Using rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagrass, Hoda A., Sharaf, Samar, Pasha, Heba F., Tantawy, Enas A., Mohamed, Randa H., Kassem, Rasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482248/
https://www.ncbi.nlm.nih.gov/pubmed/26124926
_version_ 1782378407542128640
author Hagrass, Hoda A.
Sharaf, Samar
Pasha, Heba F.
Tantawy, Enas A.
Mohamed, Randa H.
Kassem, Rasha
author_facet Hagrass, Hoda A.
Sharaf, Samar
Pasha, Heba F.
Tantawy, Enas A.
Mohamed, Randa H.
Kassem, Rasha
author_sort Hagrass, Hoda A.
collection PubMed
description BACKGROUND: The potential use of microRNAs (miRNAs) as ideal tumor markers has been the focus of recent research. OBJECTIVE: Our hypothesis was that circulating miRNAs are differentially expressed in pretherapeutic sera of breast cancer patients compared to controls. MATERIALS AND METHODS: Using real-time quantitative polymerase chain reaction (qPCR) analysis, levels of 5 candidate miRNAs (miR10b, miR34a, miR155, miR195 and miR16) were quantified in sera of breast cancer patients and control individuals. RESULTS: Levels of preoperative sera showed significant upregulation of 3.36 fold rise in miR10b (p<0.001), a 2.07 fold rise in miR155 (p =0.005) and remarkable over expression of 11.9 fold rise in miR195 (p<0.001) of cases than controls. There was significant down regulation of miR34a (0.032, p<0.001). The comparison with the clinicopathological data of the breast cancer patients revealed significant high serum level of miR155 (p =0.004) and miR195 (p =0.002) in patients with lymph node metastasis and higher levels of miR10b (p =0.001) and miR155 (p <0.001) with distant metastasis (M1) than without metastasis (M0), in addition to significant decrease in miR34a (p <0.001) level in M1 than M0 cases. CONCLUSIONS: These findings suggest that systemic circulating miRNAs have potential use as novel biomarkers for breast cancer.
format Online
Article
Text
id pubmed-4482248
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44822482015-06-29 Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer Hagrass, Hoda A. Sharaf, Samar Pasha, Heba F. Tantawy, Enas A. Mohamed, Randa H. Kassem, Rasha Genes Cancer Research Paper BACKGROUND: The potential use of microRNAs (miRNAs) as ideal tumor markers has been the focus of recent research. OBJECTIVE: Our hypothesis was that circulating miRNAs are differentially expressed in pretherapeutic sera of breast cancer patients compared to controls. MATERIALS AND METHODS: Using real-time quantitative polymerase chain reaction (qPCR) analysis, levels of 5 candidate miRNAs (miR10b, miR34a, miR155, miR195 and miR16) were quantified in sera of breast cancer patients and control individuals. RESULTS: Levels of preoperative sera showed significant upregulation of 3.36 fold rise in miR10b (p<0.001), a 2.07 fold rise in miR155 (p =0.005) and remarkable over expression of 11.9 fold rise in miR195 (p<0.001) of cases than controls. There was significant down regulation of miR34a (0.032, p<0.001). The comparison with the clinicopathological data of the breast cancer patients revealed significant high serum level of miR155 (p =0.004) and miR195 (p =0.002) in patients with lymph node metastasis and higher levels of miR10b (p =0.001) and miR155 (p <0.001) with distant metastasis (M1) than without metastasis (M0), in addition to significant decrease in miR34a (p <0.001) level in M1 than M0 cases. CONCLUSIONS: These findings suggest that systemic circulating miRNAs have potential use as novel biomarkers for breast cancer. Impact Journals LLC 2015-05 /pmc/articles/PMC4482248/ /pubmed/26124926 Text en Copyright: © 2015 Hagrass et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Hagrass, Hoda A.
Sharaf, Samar
Pasha, Heba F.
Tantawy, Enas A.
Mohamed, Randa H.
Kassem, Rasha
Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title_full Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title_fullStr Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title_full_unstemmed Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title_short Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer
title_sort circulating micrornas - a new horizon in molecular diagnosis of breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482248/
https://www.ncbi.nlm.nih.gov/pubmed/26124926
work_keys_str_mv AT hagrasshodaa circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer
AT sharafsamar circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer
AT pashahebaf circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer
AT tantawyenasa circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer
AT mohamedrandah circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer
AT kassemrasha circulatingmicrornasanewhorizoninmoleculardiagnosisofbreastcancer